Regulus Therapeutics Inc.
RGLS · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -25.6% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -3,732.6% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -3,762.1% | – | – |
| EPS Diluted | -0.15 | -0.2 | -0.21 | -0.17 |
| % Growth | 25% | 4.8% | -23.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |